A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Status: Recruiting

Eligibility Criteria

Age: 18 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

• Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v1.1

• At least 1 lesion accessible for biopsy

• Eastern Cooperative Oncology Group Performance Status of 0 or 1

Exclusion Criteria:

• Participants with CNS metastases as the only site of active disease (Participants with controlled brain metastases; however, will be allowed to enroll)

• Participants with active, known or suspected autoimmune disease

• Participants with conditions requiring systemic treatment with either corticosteroids (> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration

• Participants with a known history of testing positive for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS)

• Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy Other protocol defined inclusion/exclusion criteria could apply

Conditions & Interventions

Interventions:
Drug: BMS-986253, Biological: Nivolumab, Biological: Ipilimumab, Other: Placebo
Conditions:
Cancer, Melanoma

More Information

Contact(s): BMS Study Connect Contact Center www.BMSStudyConnect.com - Clinical.Trials@bms.com
Principal Investigator:
Phase: Phase 1/Phase 2
IRB
Number:
System ID: NCT03400332
